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ABSTRACT
Mantle cell lymphoma (MCL) is an incurable type of 
B-cell lymphoma. It is typically composed of small-to-
medium-sized cleaved lymphoid cells with cyclin D1 
protein expression due to the chromosomal translocation 
t(11;14)(q13;q32). Even with the development of ritux-
imab, an anti-CD20 antibody drug, the long-term out-
come of patients with MCL has not improved. Recently, 
new agents have been used in clinical settings, and the 
outcome of patients with MCL is expected to improve. 
The treatment of MCL may be at a turning point from 
intensive chemotherapy to chemotherapy-free treatment. 
In this study, a recent progress in the diagnosis and 
treatment of MCL is reviewed.
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Mantle cell lymphoma (MCL) is a mature B-cell neo-
plasm accounting for 2%–6% of non-Hodgkin lympho-
mas.1, 2 Until 1991, the following names for lymphoma 
were used to refer to MCL: centrocytic lymphoma, 
intermediate lymphocytic lymphoma, mantle-zone 
lymphoma, lymphocytic lymphoma of intermediate 
differentiation, multiple lymphomatous polyposis, and 
mantle cell-derived lymphoma. Their association with 
a specific chromosomal abnormality (t(11;14)(q13;q32))3 
and the identification of a novel cyclin gene at the break-
point locus4 lead to the identification of MCL.5 In most 
patients with MCL, the cyclin D1 gene CCND1 on 11q13 
is relocated adjacent to the immunoglobulin heavy chain 
gene IGH on 14q32 due to chromosomal translocation 
t(11;14)(q13;q32), and this results in the overexpression of 
cyclin D1 protein in the nucleus (Fig. 1).6
 Despite its small-to-medium-sized cells and indo-
lent clinical behavior, patients with MCL frequently 
experience relapse and have a poor prognosis even after 
intensive chemotherapy. With the development of novel 
agents, the outcomes of patients with MCL substantially 
improved even in actual clinical settings.7 This review 
discussed the recent progress in the diagnosis and 
treatment of MCL particularly focusing on the novel 
agents available in Japan, which include bendamustine, 
bortezomib, and ibrutinib.
DIAGNOSIS
Typical MCL
MCL is commonly composed of small-to-medium-sized 
cleaved lymphoid cells, which are proliferating diffusely 
or vaguely in the nodules. Immunohistochemistry of 
lymphoma cells shows positivity for CD5, CD10, CD19, 
CD20, CD79a, and cyclin D1. Cyclin D1 positivity in 
the nucleus due to typical chromosomal translocation 
t(11;14)(q13;q32) supports the diagnosis, although cyclin 
D1 is also overexpressed in patients with multiple my-
eloma with the same chromosome aberration and hairy 
cell leukemia without any translocation, both of which 
are readily differentiated by the typical characteristics 
of their morphology and clinical presentation. MCL is 
usually in advanced stage when diagnosed, and extran-
odal involvement is common. The clinical course is 
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FIGURE LEGENDS 
Fig. 1. Immunohistochemistry of cyclin D1 protein. Cyclin D1 protein was positive in the 
nuclei of mantle cell lymphoma cells. 
Figure 1. 
Fig. 1. Immunohistochemistry of cyclin D1 protein. Cyclin D1 
protein was positive in the nuclei of mantle cell lymphoma cells.
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indolent, and relapse frequently occurs after the standard 
chemotherapy for non-Hodgkin lymphoma. The MCL 
international prognostic index (MIPI) was elaborated 
with 455 patients with advanced stage MCL.8 The index 
was composed of age, Eastern Cooperative Oncology 
Group performance status, lactate dehydrogenase level, 
and white blood cell count, and it was modified with the 
incorporation of Ki-67 positivity.9 Furthermore, tumor 
cells can be detected using polymerase chain reaction 
in the peripheral blood and/or bone marrow in 90% 
of patients with advanced MCL upon diagnosis, and 
minimal residual disease assessment at the level of 10-5 
has an impact on predicting prognosis.10 In addition, 
cyclin D1-negative MCL exist with cyclin D2 or cyclin 
D3 overexpression, which may substitute cyclin D1.11 
Cyclin D1 negativity is associated with better prognosis 
independent from other risk factors.12
Leukemic non-nodal MCL
t(11;14)(q13;q32) with complex cytogenetics expressing 
cyclin D1 mRNA was observed in a patient with pro-
lymphocytic leukemia.13 Then, the leukemic variants 
of MCL were repeatedly reported.14 Among them, the 
indolent subtype of leukemic MCL was considered as 
leukemic non-nodal MCL, which developed through a 
pathway different from that of typical MCL.15, 16 This 
subtype is notably lacking in the expression of SOX11 
protein, which is highly expressed in typical MCL.16
Blastoid and pleomorphic variant of MCL
The acquisition of TP53 mutations and other oncogenic 
abnormalities leads to the blastoid and pleomorphic vari-
ants of MCL that have poor prognosis.17, 18 These cases 
often have tetraploid DNA contents.19 The emergence of 
tetraploids can be recapitulated with mouse fibroblasts 
transduced with TP53 mutation that are selected under 
K condition.20 In evolutionary biology, K-selection was 
initially used to describe species evolution in isolated 
islands; K is the carrying capacity of the environment, 
i.e., the number of individuals in a population of a 
given species at the population equilibrium. Thus, the 
development of these variants may be associated with K 
selection during the evolution of MCL cells.
In-situ mantle cell neoplasia
Cells with cyclin D1 protein overexpression may be in-
cidentally found in the mantle zone of lymphoid follicles 
in otherwise reactive lymph nodes. These cells may be 
the precursors of MCL; however, a low risk of develop-
ing overt MCL was observed.16
TREATMENT
Rituximab-based intensive chemotherapy
With the development of rituximab, anti-CD20 antibody 
drug, immunochemotherapy with rituximab, cyclo-
phosphamide, doxorubicin, vincristine, and prednisone 
(R-CHOP) has substantially improved the outcome of 
patients with aggressive B-cell lymphomas. However, 
the long-term outcome of patients with MCL has not 
improved with the R-CHOP regimen. Intensive immu-
nochemotherapy regimens, such as rituximab-based 
hyperfractionated cyclophosphamide, vincristine, 
doxorubicin, and dexamethasone alternating with 
high-dose methotrexate and cytarabine (R-HCVAD/
MA), and MCL2 protocols conducted by the Nordic 
Lymphoma Group have significantly improved the 
outcomes of younger patients with MCL in general 
(median overall survival [OS]: 11-13 years), which 
impressed the efficacy of high-dose cytarabine as the 
frontline treatment of MCL (Table 1).21, 22 Furthermore, 
rituximab-based chemotherapy with high-dose cytar-
abine followed by autologous stem cell transplantation 
and rituximab maintenance was a better approach for 
younger patients with MCL in randomized studies.23, 24 
Even after the introduction of intensive chemotherapy, 
MIPI can still discriminate risk groups and identify 
patients with poor prognosis.25 Recently, Eskelund et al. 
have evaluated the prognostic value of recurrent genetic 
aberrations in MCL and found that TP53 mutations but 
not deletions retained the prognostic impact for OS in 
multivariate analyses.26 TP53-mutated MCL cells may 
not be eradicated by intensive therapy, and patients 
with TP53-mutated MCL still have a dismal outcome 
with a median OS of 1.8 years.26 Thus, new treatment 
strategy using novel agents other than intensive che-
motherapy should be explored for patients with TP53 
mutations. Intriguingly, MIPI loses the potency of risk 
discrimination in patients without TP53 mutations, and 
this indicated the need for a new prognostic model other 
than MIPI.
Bendamustine
Bendamustine is composed of two chemical structures. 
One is that of alkylating agents and the other is that of 
purine analogues. It was developed in East Germany in 
the Cold War era and found to be effective for non-Hodgkin 
lymphoma in the 21st century. Bendamustine plus 
rituximab is the first regimen that is non-inferior to the 
R-CHOP regimen for the treatment of untreated indolent 
lymphoma and MCL in the randomized clinical trial 
(Table 2).27, 28 Because of fewer toxic effects, bendamus-
tine is a preferred substitute for all 4 drugs of the CHOP 
regimen. Compared with the R-HCVAD/MA regimen 
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Table 1. Selective studies of intensive immunochemotherapy for untreated MCL
Phase Treatment n Median age, years (range)
OR, % 
(CR) Survival TRM Reference
II
single-center R-HCVAD/MA 97 61 (41–80) 97 (87)
median FFS: 4.8 years, OS: 10.7 
years,
5-years FFS: 49%, OS: 67%,
10-year FFS: 26%, OS: 52%
15-year FFS: 22%, OS: 33%
4% Chihara et al. 201621
II 
multicenter
R-Maxi-CHOP + HDA 
+ ASCT (MCL2) 159 56 (32–65) 96 (82)
median PFS: 8.5 years, OS: 12.7 
years 5%
Eskelund 
et al. 201622
III
randomized
R-CHOP 
+ dexa-BEAM/TC-ASCT vs 
R-CHOP/R-DHAP 
+ TAM-ASCT
234
vs
232
55 
(IQR: 49–60)
97 (76)
vs
98 (83)
5-year TTF: 40% vs 65%, OS: 
68% vs 76%
median TTF: 3.9 years vs 9.1 
years, OS: NR vs 9.8 years
3.4%
vs
3.4%
Hermine 
et al. 201623
III 
randomized
R-DHAP + ASCT + none 
vs Rm
299
(120 vs 120)* 57 (27–65) 83 (77)
4-year PFS: 68%, OS: 78%
4-year EFS: 61% vs 79%, OS: 
80% vs 89%*
4% Le Gouill et al. 201724
II
multicenter
R-High-CHOP/CHASER 
+ LEED-ASCT 45 59 (35–65) 96 (82)
median PFS 3.7 years, 
2-year PFS 77%
5-year PFS: 52%, OS: 71%
0% Ogura et al. 201847
*after transplantation.
ASCT, autologous stem cell transplantation; CHASER, cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and 
rituximab; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; CR, complete response rate; dexa-BEAM/TC, dexameth-
asone, carmustine, etoposide, cytarabine, and melphalan/total body irradiation and cyclophosphamide; DHAP, dexamethasone, high-
dose cytarabine, and cisplatin; EFS, event-free survival; FFS, failure-free survival; HCVAD/MA, hyperfractionated cyclophosphamide, 
vincristine, doxorubicin, and dexamethasone alternating with high-dose cytarabine and methotrexate; HDA, high-dose cytarabine; IQR, 
interquartile range; LEED, melphalan, cyclophosphamide, etoposide, and dexamethasone; MCL, mantle cell lymphoma; n, number of 
patients; NR, not reached; OR, overall response rate; OS, overall survival; PFS, progression-free survival; R, rituximab; Rm, rituximab 
maintenance; TAM, total body irradiation, high dose cytarabine, and melphalan; TRM, treatment-related mortality; TTF, time-to-
treatment failure. 
Table 2. Selective studies of bendamustine-based therapy for untreated MCL
Phase Treatment n Median age, years (range)
OR, % 
(CR) Survival TRM Reference
III
randomized R-Bendamustine vs R-CHOP 46 vs 48 70 (65–74)
93 (40)* 
vs 
91 (30)*
median PFS: 35.4 months 
vs 22.1 months
0.4%* 
vs 
2.0%*
Rummel 
et al. 201327
III
randomized
R-Bendamustine vs 
R-CHOP/R-CVP 34 vs 33
60 (28–84)* 
vs 
58 (25–86)*
94 (50)
vs 
85 (27)
NA
0.5%*
vs 
0.5%*
Flinn 
et al. 201428
II
two-center
R-Bendamustine 
+ HDA + ASCT 23 57 (42–69) 96 (96) 1-year PFS: 96%, OS: 96% 0%
Armand
et al. 201630
II 
randomized, 
closed 
prematurely
R-HCVAD/MA + ASCT
 vs 
R-Bendamustine + ASCT
17 vs 35
59 (44–66) 
vs 
57 (33–64)
94 (35) 
vs 
83 (40)
2-year PFS: 82% vs. 81%, 
OS: 88% vs. 87% NA
Chen 
et al. 201729
II
multicenter
R-Bendamustine + low-dose 
cytarabine (RBAC500) 57 71 (61–79) 91 (91) 2-year PFS: 81%, OS: 86% 0%
Visco 
et al. 201731
*not restricted to MCL.
ASCT, autologous stem cell transplantation; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; CR, complete response 
rate; CVP, cyclophosphamide, vincristine, and prednisone; HDA, high-dose cytarabine; HCVAD/MA, hyperfractionated cyclophospha-
mide, vincristine, doxorubicin, and dexamethasone alternating with high-dose cytarabine and methotrexate; MCL, mantle cell lymphoma; 
n, number of patients; NA, not available; OR, overall response rate; OS, overall survival; PFS, progression-free survival; R, rituximab; 
TRM, treatment-related mortality.
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as a pre-transplant induction regimen for younger pa-
tients, bendamustine plus rituximab showed a similar 
efficacy, and it can achieve a deep remission with a 
better mobilization success.29 Furthermore, the phase 2 
study of immunochemotherapy followed by autologous 
stem cell transplantation for transplant-eligible patients 
with MCL using bendamustine plus rituximab and then 
high-dose cytarabine plus rituximab showed a promis-
ing result and must be further assessed in comparative 
studies.30 In addition, low-dose cytarabine instead of 
high-dose one may have a role in the treatment of MCL 
and must be studied in randomized trials.31
Table 3. Selective studies of bortezomib-based therapy for untreated MCL
Phase Treatment n Median age, years (range)
OR, % 
(CR) Survival TRM Reference
II
multicenter RiPAD + C 39 72 (65–80) 79 (59) median PFS: 26 months, OS: NR 5%
Houot 
et al. 201235
III 
randomized R-CHOP vs VR-CAP 244 vs 243 66 (26–88)
89 (42) 
vs
92 (53)
median PFS: 14.4 months vs 24.7 
months. OS: 56.3 months vs NR
4-year OS: 54% vs 64%
3% 
vs 
2%
Robak 
et al. 201532
II
two-center
Bortezomib + R + 
HCVAD/MA 95 61 (38–75) 100 (82) median TTF: 55 months 4%
Romaguera 
et al. 201836
II
four-center
Bortezomib + R + 
modified HCVAD + Rm 30 61 (48–74) 90 (77)
median PFS: 8.1 years
6-year PFS: 53%, OS: 70% 3%*
Chang 
et al. 201848
*following allogeneic stem cell transplant.
CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; CR, complete response rate; HCVAD, hyperfractionated cyclo-
phosphamide, vincristine, doxorubicin, and dexamethasone; MA, high-dose cytarabine and methotrexate; MCL, mantle cell lymphoma; 
n, number of patients; NR, not reached; OR, overall response rate; OS, overall survival; PFS, progression-free survival; R, rituximab; 
RiPAD + C, rituximab, bortezomib, doxorubicin, dexamethasone, and chlorambucil; Rm, rituximab maintenance; TRM, treatment-related 
mortality; TTF, time-to-treatment failure; VR-CAP, bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone.
Table 4. Selective studies of chemotherapy-free treatment for MCL
Phase Treatment n* Median age, years (range)
OR, % 
(CR) Survival TRM Reference
II
multicenter Ibrutinib 111 68 (40-84) 68 (21)
median PFS: 13.9 months
18-month OS: 58% 1%
Wang 
et al. 201338
II
multicenter Ibrutinib 16 72 (55-83) 88 (13) 6-month PFS: 88% 0%
Maruyama 
et al. 201649
III
randomized Ibrutinib vs temsirolimus 280 68 (IQR: 13)
72 (19) 
vs 
40 (1)
median PFS: 14.6 months vs 
6.2 months
1-year OS: 68% vs 61%
6% 
vs 
8%
Dreyling 
et al. 201639
II
single-center Ibrutinib and rituximab 50 67 (45–86) 88 (44) 1-year PFS: 75%, OS: 86% 2%
Wang 
et al. 201643
II
multicenter Lenalidomide and rituximab 38
† 65 (42–86) 92 (64) 3-year PFS: 80%, OS: 90%,5-year PFS: 64%, OS: 77% 0%
Ruan 
et al. 201845
II
two-center Ibrutinib and venetoclax 24
‡ 68 (47–81) 71 (71) 1-year PFS: 75%, OS: 79% 8% Tam et al. 201846
*relapsed or refractory MCL if not otherwise described. †untreated MCL. ‡not restricted to relapsed or refractory MCL.
CR, complete response rate; IQR, interquartile range; MCL, mantle cell lymphoma; n, number of patients; OR, overall response rate; OS, 
overall survival; PFS, progression-free survival; TRM, treatment-related mortality. 
Bortezomib
Bortezomib is the first proteasome inhibitor used in 
clinical practice. The use of bortezomib rather than 
vincristine in the standard R-CHOP regimen (VR-CAP) 
had a better efficacy than the R-CHOP regimen for 
transplant-ineligible patients at the cost of increased he-
matologic toxicity (Table 3).32 The post-hoc analysis of 
this study showed the clear relationship between higher 
cumulative bortezomib dose and longer OS, and this 
result indicates the role of bortezomib in the treatment 
strategy for elderly patients with MCL in the condition 
of improved supportive care and optimization of bor-
tezomib dose.33 Notably, bortezomib-based therapy is 
associated with a high incidence of painful peripheral 
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neuropathy and herpes zoster, which requires dose ad-
justment and antiviral prophylaxis particularly in elderly 
patients.34-36 
Ibrutinib
Ibrutinib is a first-in-class drug taken once daily via oral 
route, and it is a covalent inhibitor of Bruton tyrosine 
kinase, which is important for signaling via B-cell 
receptors and other B-cell surface receptors. Ibrutinib 
binds covalently to the kinase and inhibits B-cell recep-
tor signaling leading to downstream mitigation of cell 
growth, proliferation, survival, adhesion, and migration. 
Bruton tyrosine kinase is commonly overexpressed in 
MCL, and its inhibition by ibrutinib induces apoptosis.37 
A phase 2 study of ibrutinib involving patients with re-
lapsed or refractory MCL had the best overall response 
rate (OR) of 68%, a complete response rate (CR) of 
21%, and a median progression-free survival (PFS) of 
13.9 months,38 and a phase 3 trial had an OR of 72%, a 
CR of 19%, and a median PFS of 14.6 months (Table 
4).39 Interestingly, as observed in patients with chronic 
lymphoid leukemia, ibrutinib dose-dependently inhibits 
the adhesion and migration of MCL cells, resulting 
in transient lymphocytosis in patients with MCL who 
experience bone marrow involvement.40, 41 The common 
or serious side effects of ibrutinib include bleeding due 
to platelet dysfunction,42 diarrhea, rash, and atrial fibril-
lation.38, 39
Moving towards chemotherapy-free treatment
Immunochemotherapy recommended for young fit 
patients with MCL, which is usually combined with au-
tologous stem cell transplantation, is rarely performed in 
frail patients with comorbidities and elderly patients. If 
the risk among patients with MCL is low based on MIPI, 
the “watch and wait” strategy is an option particularly 
for elderly patients. However, novel agents without severe 
adverse effects are available and are given in outpatient 
clinics. Among them, the single use of bendamustine or 
in combination with rituximab is effective. Alternatively, 
chemotherapy-free regimens are preferred for elderly 
patients because it causes less severe hematologic toxic-
ity. Ibrutinib can be administered orally, and the dose is 
adjusted for each patient. In addition, the combination of 
ibrutinib and rituximab showed favorable results for the 
treatment of relapsed MCL in the single-center phase 
2 trial (Table 4).43 Although ibrutinib antagonized the 
rituximab anti-lymphoma effect in a mouse model partly 
via the off-target inhibition of interleukin-2-inducible 
tyrosine kinase in natural killer cells,44 a randomized 
trial of ibrutinib with rituximab against standard immu-
nochemotherapy as first-line therapy is being conducted 
(EudraCT Number: 2015-000832-13).
 Furthermore, lenalidomide, a second-generation im-
munomodulatory compound, is an emerging new player 
in the treatment of lymphoma, and it was approved for 
the treatment of patients with relapsed or refractory 
MCL by the Food and Drug Administration in the 
Unites States in 2013. It has been approved in Japan for 
adult T-cell leukemia/lymphoma. A long-term follow-up 
in the phase 2 study of the R-squared regimen, i.e., lena-
lidomide and rituximab, for untreated MCL had 5-year 
PFS of 64% and OS of 77%; The OR was 92% and CR 
was 64%.45 A randomized phase 3 trial on lenalidomide 
compared with placebo in combination with rituximab 
is being conducted for the treatment of relapsed or 
refractory indolent lymphoma (ClinicalTrials Number: 
NCT01938001), and favorable results were observed. 
Another emerging compound is venetoclax, a BCL-2 in-
hibitor, which has been approved by the Food and Drug 
Administration for the treatment of chronic lymphocytic 
leukemia/small lymphocytic lymphoma. The combina-
tion of venetoclax and ibrutinib improved the outcome 
of patients with MCL who had been predicted to have 
poor outcomes with current therapy.46
CONCLUSION
For young fit patients with MCL, intensive immunoche-
motherapy with autologous stem cell transplantation is 
still recommended. However, novel approaches should 
be examined for a high-risk subgroup of patients with 
TP53 mutations. In addition, less intensive regimens 
using new agents should be compared with intensive ap-
proaches, and the establishment of frontline chemotherapy-
free treatment is eagerly awaited. We should focus on 
the progress of clinical trials on new agents since we are 
at a turning point from intensive immunochemotherapy 
to less toxic chemotherapy-free treatment. In the near 
future, the outcome of patients with MCL is expected to 
be further improved.
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